FRANKLIN LAKES, N.J., Feb. 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2026 first quarter, which ended December 31, 2025. "We delivered strongerthanexpected firstquarter performance which reflects our disciplined execution, including accelerated commercial initiatives and broadbased growth across key end markets," said Tom Polen, chairman, CEO and president of BD. "Today, we expect to complete the ...

Core Viewpoint - Peijia Medical Limited has submitted the CE Mark registration application for its GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System, marking a significant step in its globalization strategy and commitment to expanding in international markets [2][4]. Group 1: Product Development - The GeminiOne TEER device features a unique sliding groove mechanism for longer coaptation length while maintaining a smaller implant size and delivery system [3]. - It incorporates an independent leaflet grasping design to reduce procedural complexity, an auto-locking mechanism to prevent repeated locking and unlocking, and a multi-angular detachment capability for accommodating various anatomical variations [3]. - The design has been patented globally and has passed multiple freedom-to-operate analyses [3]. Group 2: Regulatory Progress - In addition to the EU submission, the GeminiOne registration application has been accepted by the National Medical Products Administration (NMPA) of China and is under review [4]. - The system has received Investigational Device Exemption (IDE) approval from the U.S. FDA for an Early Feasibility Study in the United States [4]. Group 3: Company Overview - Peijia Medical, established in 2012 and headquartered in Suzhou, China, focuses on the interventional procedural medical device market and aims to become a leading global medical device platform for structural heart and neurovascular diseases [8]. - The company currently has four TAVR systems and nearly twenty neurointerventional devices registered in China, along with various innovative product candidates at different development stages [8].

Core Viewpoint - Boston Scientific Corporation is under investigation for potential violations of federal securities laws following its fourth-quarter 2025 earnings report, which revealed a significant shortfall in its electrophysiology segment sales compared to market expectations [1][5]. Financial Performance - Boston Scientific reported fourth-quarter 2025 earnings, exceeding analyst expectations for earnings per share and total revenue, but its electrophysiology segment sales were $890 million, approximately $43 million below the consensus estimate of $933 million [2]. - The company had previously guided for organic growth of 11% to 13% for the fourth quarter, but management indicated confidence in only about 15% growth going forward, which is significantly lower than the market's expectation of approximately 25% [4][5]. Market Dynamics - The electrophysiology market is one of the fastest-growing areas in cardiovascular medicine, with pulsed field ablation technology emerging as a potential alternative to traditional thermal ablation procedures [3]. - Boston Scientific entered this market through its acquisition of Farapulse in 2021 and has made substantial investments in expanding manufacturing capacity and physician training programs [3]. Growth Projections - The company projected that global penetration of pulsed field ablation technology would reach 50% by the end of 2025 and grow to approximately 80% by 2028 [3]. - The company emphasized strong growth rates in its electrophysiology segment, reporting 94% growth in Q2 2025 and 63% growth in Q3 2025 [4]. Stock Market Reaction - Following the earnings release, Boston Scientific's shares fell by 17.5%, reaching a 52-week low of $75.50, indicating a negative market reaction to the earnings report and growth outlook [5].

Group 1 - The core focus of the news is the upcoming IPO of Changzhou Tongbao Optoelectronics Co., Ltd. (stock code: 920168), a significant supplier in the LED automotive lighting sector, which is set to open for subscription on February 9, 2026 [1][3][4]. - Tongbao Optoelectronics specializes in the production and application of LED semiconductor lighting devices, covering automotive LED modules and lighting design and manufacturing [1][4][5]. - The company has established strategic partnerships with major automotive manufacturers, including SAIC-GM-Wuling, which is its largest customer [1][5]. Group 2 - The subscription limit for Tongbao Optoelectronics is set at 845,700 shares, with a total fundraising target of approximately 13.675 million yuan [4]. - The company was founded in 1991 and has developed a comprehensive production capability for various LED automotive lighting products, serving both domestic and international automotive manufacturers [5]. - The company is positioned to benefit from the rapid growth of domestic new energy vehicle brands and has participated in the development of several popular new energy models [5]. Group 3 - Other companies scheduled for IPO during the same week include Electric Science and Technology Blue Sky Co., Ltd. (688818), Anhui Linping Circular Development Co., Ltd. (603284), and Suzhou Aide Technology Development Co., Ltd. (920180) [6]. - Electric Science and Technology Blue Sky focuses on energy products and systems, while Linping Development specializes in corrugated paper and boxboard, and Aide Technology is involved in orthopedic medical devices [6]. Group 4 - The news also highlights recent IPO approvals, including Anhui New Fortune New Energy Technology Co., Ltd. and Guangdong Huahui Intelligent Equipment Co., Ltd., which successfully passed the review for listing on the Beijing Stock Exchange [8][9]. - The upcoming review for Changzhou Longxin Intelligent Equipment Co., Ltd. and Henan Jiachen Intelligent Control Co., Ltd. is scheduled for February 11 and 12, respectively [9][10]. Group 5 - In the Hong Kong market, companies such as Haizhi Technology Group and Wolong Nuclear Materials are set to open for subscription [11]. - Shenzhen Luyuan Technology Co., Ltd. has submitted its IPO prospectus in Hong Kong, while Danuo Pharmaceutical (Suzhou) Co., Ltd. has updated its prospectus [11]. Group 6 - Recent financing activities include Henan Zhongke Qingneng Technology Co., Ltd. completing nearly 500 million yuan in Pre-A++ financing, and other companies like Zhuosheng Technology and Suzhou Linghou Robot Co., Ltd. also securing significant funding [15][16].

Core Insights - Fundsmith's equity portfolio is valued at approximately $19–20 billion, focusing on high-quality global consumer and technology franchises with strong pricing power and high returns on capital [1][2] - The portfolio structure remains stable, with significant trims in several mega-cap technology positions and selective additions to existing compounders [1][2] Portfolio Overview - Total Portfolio Value: ~$19–20 billion [2] - Top 10 Holdings account for approximately 65–70% of the portfolio [2] - Moderate turnover indicates rebalancing rather than a change in strategy [2] Major Holdings - Top Holdings & Weights: - Stryker (SYK): ~$1.70 billion (~8.6%) - IDEXX Laboratories (IDXX): ~$1.67 billion (~8.4%) - Alphabet (Class A) (GOOGL): ~$1.53 billion (~7.7%) - Microsoft (MSFT): ~$1.34 billion (~6.8%) - Visa (V): ~$1.32 billion (~6.7%) - Automatic Data Processing (ADP): ~$1.27 billion (~6.4%) - Waters (WAT): ~$1.19 billion (~6.0%) - Philip Morris International (PM): ~$1.17 billion (~5.9%) - Meta Platforms (META): ~$1.14 billion (~5.8%) - Marriott International (MAR): ~$1.10 billion (~5.6%) [2] Portfolio Adjustments - Major Trims: - Microsoft: Shares reduced by ~2.36 million (-48% QoQ) - Meta Platforms: Shares cut by ~2.01 million (-56% QoQ) - Philip Morris International: Trimmed by ~1.89 million shares (-21% QoQ) - Alphabet (Class A): Reduced by ~514k shares (-7.6% QoQ) [5] - Notable Adds: - Waters: Added ~347k shares (+9.6% QoQ) [5] - Smaller increases in Visa, Procter & Gamble, and Fortinet indicate steady compounding exposure [5] Investment Philosophy - Fundsmith emphasizes a quality-first investment approach, willing to rebalance positions based on valuations and portfolio risk without altering its core philosophy [2][7] - The recent adjustments reflect portfolio optimization rather than repositioning, maintaining a focus on exceptional businesses for long-term growth [8]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Integer Holdings Corporation during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Integer common stock between July 25, 2024, and October 22, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 9, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Integer Holdings - The lawsuit alleges that Integer Holdings made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market [5]. - It is claimed that Integer overstated its visibility into customer demand while experiencing a decline in sales for two of its electrophysiology devices [5]. - The lawsuit asserts that Integer mischaracterized its electrophysiology devices as long-term growth drivers for its cardio and vascular segment, leading to misleading positive statements about its business and operations [5].

Core Insights - Intuitive Surgical is a leader in robotic surgery, with its Da Vinci surgical robot being widely used in various minimally invasive procedures [2][6] - The company has demonstrated consistent earnings growth and strong stock market performance, making it a compelling investment opportunity [2][6] Product Overview - Intuitive Surgical offers four versions of the Da Vinci surgical robot, including the value-focused Da Vinci X and the latest Da Vinci 5, which features over 150 design innovations [4] - The Da Vinci platform is favored by surgeons due to extensive training and hospitals' significant investments in the technology, creating a strong competitive advantage [5] Financial Performance - In the most recent quarter, Intuitive Surgical grew its installed base of systems by 12% to over 11,000, with revenue increasing by 19% to more than $2.8 billion [6] - Procedure growth rose by 18%, and net income increased by 16% to $794 million [6] Revenue Streams - The sale or lease of Da Vinci systems generates recurrent revenue through instruments and accessories, which are disposable and need to be replaced regularly [7][8] - In the recent quarter, instruments and accessories revenue reached $1.6 billion, significantly surpassing the $785 million generated from robotic systems sales [8]

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, significantly below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6]. Legal Proceedings - Investors have until February 9, 2026, to request to be appointed to lead the case, which is currently pending in the U.S. District Court for the Southern District of New York [3]. The case is titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. Investor Information - Investors in Integer are encouraged to seek additional information regarding their legal options and can submit their information to the law firm representing the class action [2][7].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased Tandem Diabetes securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Company Incident and Stock Impact - On August 7, 2025, Tandem Diabetes issued a press release regarding a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following this announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Picard Medical, Inc. securities during the specified Class Period, highlighting potential compensation for affected investors [1][2]. Group 1: Class Action Details - The class action lawsuit pertains to securities purchased between September 2, 2025, and October 31, 2025 [1]. - Investors who purchased Picard Medical securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Process and Participation - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by April 3, 2026, to represent the class in court [1][3]. Group 3: Allegations Against Picard Medical - The lawsuit alleges that defendants made materially false and misleading statements and failed to disclose adverse facts about Picard's business and operations [5]. - Specific allegations include involvement in a fraudulent stock promotion scheme, insider trading through offshore accounts, and omission of critical information regarding stock price manipulation [5]. Group 4: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with notable achievements in previous years [4].